What changed
Lilly reported phase 3 retatrutide results over 80 weeks in adults with obesity and type 2 diabetes; it said results were presented at EASD and published in The Lancet.
What the evidence does not settle
Sponsor release, not independent full-paper extraction. Efficacy-estimand headlines need full safety, discontinuation and treatment-regimen context. Retatrutide remained investigational.
Evidence record
Event date: 2026-09-29. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.